Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases

Area of Science:

• Rheumatology
• Immunology
• Pulmonary Medicine

Background:

• Fibrosis is a significant complication of chronic rheumatic diseases, leading to severe illness and death.
• Current antifibrotic treatments are insufficient to halt disease progression, particularly in pulmonary fibrosis.
• There is a critical need for novel therapeutic strategies to manage fibrotic conditions.

Purpose of the Study:

• To review recent findings on therapeutic targets for treating fibrosis.
• To explore the potential of Interleukin-11 and Fibroblast Activation Protein (FAP) as targets for antifibrotic therapies.

Main Methods:

• Literature review of recent studies on fibrotic diseases and potential therapeutic targets.
• Analysis of the role of Interleukin-11 as a fibrogenic cytokine.
• Examination of Fibroblast Activation Protein (FAP) expression and targeting strategies.

Main Results:

• Interleukin-11 is identified as a key fibrogenic cytokine, amenable to blockade by monoclonal antibodies.
• Fibroblast Activation Protein (FAP) is highly expressed on activated fibroblasts in fibrotic tissues.
• Targeting FAP, explored in cancer therapy, shows potential for treating rheumatic disease fibrosis.

Conclusions:

• Interleukin-11 and FAP represent emerging and viable therapeutic targets for fibrosis.
• Targeting these pathways may offer new avenues for managing fibrosis in rheumatic diseases and pulmonary fibrosis.
• Further research into FAP-targeting modalities could translate to effective antifibrotic treatments.